VictorRiveraMD

PubMed

• RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
  Gozgit, J. M.,Chen, T. H.,Song, Y.,Wardwell, S.,Wang, F.,Cai, J.,Li, H.,Edgren, H.,Rivera, V. M.,Pritchard, J.> ;Oncotarget. 2018 Jul 25
• The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
  Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang W, Liu S, Zou D, Wang Y, Mohemmad Q, Jan...> ;Clin. Cancer Res.. 2016-10-25
• Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
  Huang W, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J, Cai L, Dwight TA, Xu Y, Xu R, Dodd R, Toms A, Parillon L, Lu X, Anjum R, Zhang S, Wa...> ;J. Med. Chem.. 2016-05-26
• Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
  Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Riv...> ;Lancet Oncol.. 2016-05-01
• The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
  Parker WT, Yeung DTO, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S> ;Blood. 2016-04-14
• Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
  Deininger, M. W.,Hodgson, J. G.,Shah, N. P.,Cortes, J. E.,Kim, D. W.,Nicolini, F. E.,Talpaz, M.,Baccarani, M.,Müller, M. C.,Li, J.,Parker, W. T.,Lustgarten, S.,Clackso...> ;Blood. 2015 Nov 26
• Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients.
  Garner, A. P.,Gozgit, J. M.,Anjum, R.,Vodala, S.,Schrock, A.,Zhou, T.,Serrano, C.,Eilers, G.,Zhu, M.,Ketzer, J.,Wardwell, S.,Ning, Y.,Song, Y.,Kohlmann, A.,Wang, F.,Cl...> ;Clin. Cancer Res.. 2014 Sep 23
• A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
  Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccar...> ;N. Engl. J. Med.. 2013-11-07
• Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
  Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM> ;Cancer Chemother. Pharmacol.. 2013-05-01
• Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
  Kohlmann A, Zech SG, Li F, Zhou T, Squillace RM, Commodore L, Greenfield MT, Lu X, Miller DP, Huang W, Qi J, Thomas RM, Wang Y, Zhang S, Dodd R, Liu S, Xu R, Xu Y, Mir...> ;J. Med. Chem.. 2013-02-14
• Ponatinib in refractory Philadelphia chromosome-positive leukemias.
  Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MWN, Ta...> ;N. Engl. J. Med.. 2012-11-29
• Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
  Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM> ;Int. J. Oncol.. 2012-08-01
• Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
  Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM> ;Mol. Cancer Ther.. 2012-03-01
• Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
  Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, Mohemmad QK, Anjum R, Wang Y, Narasimhan NI, Dalgarno D, Shakespeare WC, Miret JJ, Clackson T, Rivera VM> ;Chem Biol Drug Des. 2011-12-01
• The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
  O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ> ;Blood. 2011-11-10
• Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
  Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, Wang F, Clackson T, Rivera VM> ;Mol. Cancer Ther.. 2011-10-01
• Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
  Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM> ;Mol. Cancer Ther.. 2011-06-01
• Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
  Rivera, V. M.,Squillace, R. M.,Miller, D.,Berk, L.,Wardwell, S. D.,Ning, Y.,Pollock, R.,Narasimhan, N. I.,Iuliucci, J. D.,Wang, F.,Clackson, T.> ;Mol. Cancer Ther.. 2011 Apr 13
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
  O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang W, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats J...> ;Cancer Cell. 2009-11-06
• A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
  Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ> ;Clin. Cancer Res.. 2009-02-15
• A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malign...
  Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ> ;Clin. Cancer Res.. 2008-05-01
• Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer.
  Rivera VM, Gao G, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, Wilson JM> ;Blood. 2005-02-15
• Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
  O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D,...> ;Blood. 2004-10-15
• Join now to see all